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Respiratory diseases represent a major healthcare burden worldwide. Lung transplantation (LTx) is the "gold standard" for end-stage patients, strongly limited by shortage of available/suitable donor lungs. Normothermic ex vivo lung perfusion (EVLP) has significantly increased the number of lungs suitable for transplantation. Steen solution is used for EVLP, but the mechanisms involved in its beneficial properties remain to be clarified. We investigated the effects of Steen solution in an in vitro protocol of cold starvation and normothermic recovery on human lung spheroids, named pneumospheres (PSs), containing epithelial/basal cells, and on endothelial human umbilical vein endothelial cells (HUVEC). Steen solution significantly preserved the viability of PSs, reduced reactive oxygen species (ROS) release by PSs and HUVECs, decreased NADPH-oxidase (NOX) activity in PSs, and reduced inflammatory cytokines expression levels in HUVECs. Steen solution was able to specifically reduce NADPH oxidase 2 (NOX2) isoform activation, particularly in PSs, as detected by soluble-NOX2 peptide and p47-phosphorylation. Interestingly, a specific NOX2 inhibitor could partly mimic the pro-survival effect of Steen on PSs. We provide the first evidence that Steen solution can preserve lung epithelial/progenitor cells viability partially through NOX2 downregulation, and exert antioxidant effects on parenchymal cells, with consequent ROS reduction. These results suggest that NOX2 inhibition might be an additional strategy to reduce cellular damage during LTx procedures.
Introduction
Chronic lung diseases represent one of the biggest healthcare burdens worldwide, with lung transplantation (LTx) being the only effective treatment for end-stage patients. Despite multiple optimization strategies, the number of patients on the waiting lists still far exceeds that of available and suitable donor lungs. In recent years, novel preservation and functional assessment techniques have contributed to the significant reduction of rejected organs (1): normothermic ex vivo lung perfusion (EVLP) allows functional reassessment and reconditioning to make marginal lungs suitable for LTx.
The state-of-the-art EVLP protocol is based on progressive lung rewarming up to normothermia and acellular/ cellular perfusates with increased colloid osmotic pressure. One of these priming formulations is the Steen solution, which is used in two protocols, Lund and Toronto (2) . The success of EVLP seems to be related, among others, to the specific properties of perfusion solutions, such as the Steen (2) . Nonetheless, the specific mechanism through which it preserves and/or restores lung function still needs full clarification.
EVLP has indeed increased the donor organs pool by preserving high-risk lungs, such as those collected after cardiocirculatory death (3), likely by reducing ischemiareperfusion injury (IRI) (4, 5) . Reactive oxygen species (ROS) are key IRI mediators; therefore, understanding the mechanisms of tissue protection during EVLP may help uncover novel strategies for ROS reduction. This would improve the efficacy of EVLP and perfusion solutions in expanding the pool of suitable donor lungs. We have recently provided evidence of the antioxidant properties of Steen solution on platelets and immune cells (lymphocytes/monocytes and polymorphonuclear leukocytes) (6) . However, its ability to reduce ROS in lung parenchymal cells and the involved mechanisms has not been investigated.
Lung tissue homeostasis and regeneration depend on pneumocytes and multiple resident progenitor populations, either specialized or facultative, able to dedifferentiate and/or transdifferentiate following different types of injury, including LTx (7) (8) (9) . Representative in vitro models of microtissue structures can be useful to study molecular pathways involved in cell damage response. Recently a model of spheroids containing epithelial/basal cells and lung progenitor cells (LPCs) with translational potential has been described (10) , and further characterized by our group (11) as spontaneous niche-like pneumospheres (PSs). PSs isolated from young patients with benign disease can mimic ex vivo lung epithelial cells from potential donor organs, and be a model for studying the molecular pathways responsible for lung cell protection in EVLP.
Considering our previous results on immune cells (6) , and since epithelial cell injury and endothelial dysfunction are among the main pathogenetic events of primary graft dysfunction (PGD) (12), we hypothesized that the antioxidant properties of the Steen solution may be responsible for cytoprotective effects on parenchymal (epithelial, LPCs) and endothelial cells, sustaining the response to lung damage and/or regeneration. Thus, we investigated the effects of the Steen solution and cell-type specific mechanisms on PSs, made of epithelial/basal cells and LPCs, and on the endothelial cell line human umbilical vein endothelial cells (HUVEC), subjected to in vitro cold starvation followed by normothermic recovery, providing novel significant insights on the beneficial effects of Steen solution on parenchymal cell types.
Materials and Methods
Sample collection, processing, and cell cultures Lung tissue was obtained from three patients (one female aged 26, two males aged 18 and 20) undergoing thoracic surgery for benign diseases at the Division of Thoracic Surgery, "Sant'Andrea" Hospital ("Sapienza" University of Rome), under an Institutional review board-approved protocol, and after informed consent. Biopsies were obtained during Video Assisted Thoracoscopic Surgery procedures using a mechanical stapler (ECHELON ENDOPATH TM ; Ethicon Endo-Surgery, Somerville, NJ). Biopsies were stored in saline solution at 4°C, and transferred to the laboratory for processing. Cell culture was based on progenitor cell spheroids protocols (10, 11, 13) . Experiments were performed separately on each donor's cell line, with multiple experimental replicates for each line, when possible. See Data S1 for detailed cell culture protocols of PSs and HUVECs, and for molecular biology and biochemical methods.
In vitro protocol of cold starvation and normothermic recovery (CS/NR) After thorough washes with phosphate-buffered saline (PBS), cell cultures were covered with ice-cold Celsior solution (Genzyme, Cambridge, MA) (14) ; plates were incubated at 4°C for 16 h. Cold starvation took place in minimal nutrient support (i.e. only in presence of the mannitol content of Celsior), which is nonetheless a sufficiently suboptimal metabolic condition for PS cell culture to be considered as starvation. For the 4-h recovery period, Celsior was removed and different ice-cold media/solutions were added: CEM (complete explant medium; see Data S1 for recipe), Steen solution (100%, 50%, 20%, or 10% diluted in PBS; XVivo Perfusion), PBS with 0.7 or 7% human serum albumin (HSA; Grifols, Barcelona, Spain), PBS with 50 lM NOX2, NOX4, or NOX5 inhibitors, respectively, gp91ds-tat (AnaSpec, Fremont, CA), GKT137831, and KN-93 (both Cayman Chemical, Ann Arbor, MI). Plates were immediately transferred into CO 2 incubators at 37°C ( Figure S1A ).
Statistical analysis
Results are presented as mean valueAEstandard error of the mean, unless specified. When necessary, interpatient variability was controlled for by normalizing experimental results versus each patient's control culture, considered as internal reference, and averaging fold-change modulations among patients. After variance testing, we evaluated the significance of differences among groups by one-way or two-way analysis of variance, two-sided Student's t-test, with Bonferroni correction for multiple comparisons when multiple groups were compared, or Mann-Whitney nonparametric test, as appropriate. A p-value < 0.05 was considered significant. Biological N = 3 for all experiments.
Results
In order to simulate the thermal and IRI shock of cold storage and EVLP, we reproduced an in vitro protocol of CS/NR under atmospheric conditions. PSs and HUVECs were acutely exposed to ice-cold Celsior solution (14) , and maintained at 4°C for 16 h, followed by 4 h of recovery at 37°C in the appropriate solution for each experimental design ( Figure S1A ). The temperature rise from 4°C to 37°C reached plateau in approximately 25 min ( Figure S1B ), a time frame similar to what is adopted in clinical EVLP protocols (4).
For preliminary screening in PSs, we performed recovery in either standard CEM media or Steen solution. Consistently with other reported in vitro methods to simulate cold storage (15), 16 h of cold starvation provided a reproducible condition to induce cell death ( Figure S1C ). All following experiments were performed according to these CS/NR settings. Moreover, the specific cell death susceptibility after CS/NR of PS cells with epithelial phenotype was confirmed by comparison with culture conditions promoting a stromal phenotype, as previously described (11) , showing that only epithelial cells are susceptible to cell death after CS/NR ( Figure S1D ).
We investigated the effects of Steen solution on PSs survival by dose/response experiments with serial dilutions in PBS (10%-100%). Interestingly, a dose/response effect of Steen solution on cell viability after CS/NR was observed, with 10% Steen allowing maximum viability ( Figure 1A-B Figure 1C-D) , which were instead significantly increased in PSs subjected to recovery in PBS alone. This dilution effect could be related to the specific formulation of the Steen solution, which may contain undisclosed ingredients not optimal for primary cell cultures.
Since HSA 7% is a main disclosed ingredient in Steen solution (patent US7255983-B2), we compared 10% Steen with 0.7% HSA dissolved in PBS. HSA alone yielded a total percentage of apoptotic/necrotic cells similar to recovery in PBS, significantly higher than 10% Steen (Figure 2A and B) . Nevertheless, 0.7% HSA partially but significantly reduced 8-iso-PGF2a and H 2 O 2 ( Figure 2C and D) in culture supernatants, suggesting that this component of the Steen solution may exert a partial nonspecific antioxidant effect. Moreover, to exclude possible glucose-dependent effects on oxidative stress and viability, we performed recovery of PSs in 0.7% HSA supplemented with 1 mM glucose, corresponding to the glucose concentration in 10% Steen solution. The cell death rate (particularly for AnnexinV
+ late apoptotic/necrotic cells) and ROS levels with glucose were comparable to HSA alone ( Figure 2 ). As Table S1 ) involved in PGD (12) , and CS/NR in 10% Steen significantly reduced IL-6 levels compared to PBS and 0.7% HSA (Figure 3 ).
We then investigated the molecular mechanisms whereby Steen solution reduced ROS production after CS/NR. NADPH-oxidases (NOXs) are major sources of ROS (17); therefore, we tested their gene expression and activity in our CS/NR protocol. NOX2, NOX4, and NOX5 isoforms mRNAs were detectable in PSs by realtime polymerase chain reaction ( Figure S2A ), while NOX1 was below detection limit (data not shown). Protein levels were tested by immunoprecipitation (Figure S2B) . We assessed NOX activity in our CS/NR model using a luminescence-based assay. NADPHdependent superoxide production was significantly increased in PSs subjected to CS/NR in PBS and not in 10% Steen solution ( Figure 4A and B) versus control cells.
In order to identify the NOX isoforms involved, we quantified 8-iso-PGF2a and H 2 O 2 release in PS culture supernatants after recovery in PBS supplemented with specific NOX-isoforms inhibitors ( Figure 4C-D) . NOX2-inhibitor induced the strongest reduction of 8-iso-PGF2a accumulation after CS/NR, suggesting that NOX2 might contribute the most to detrimental ROS production. H 2 O 2 production showed a similar trend. NOX isoforms expression was assessed by Western blot on PS lysates after CS/NR ( Figure 4E ), but no significant reduction was detectable. However, NOX2 activation was significantly reduced after recovery in 10% Steen compared to PBS, as detected by measurement of soluble NOX2 peptide (sNOX2-dp), a marker of NOX2 activation ( Figure 4F ), and p47-phosphorylation ( Figure 4G with NOX2 inhibitor were used as references. These results suggest that Steen solution is able to reduce posttranslational activation of NOX2.
Finally, we investigated whether NOX2 activation during CS/NR directly contributes to cell death. CS/NR in PBS supplemented with NOX2 inhibitor partially recapitulated the biological pro-survival effect of Steen solution on PSs, as assessed by AnnexinV/7AAD labeling and flow cytometry ( Figure 5A and B).
In order to study the antioxidant effects of Steen solution on the multiple cell types possibly involved in tissue injury, we exposed HUVEC endothelial cells to CS/NR with recovery in PBS, 100% Steen, 7% HSA, or culture medium. HUVECs were more resistant than PSs to cell death after CS/NR, with comparable percentages of AnnexinV + /7AAD À early apoptotic cells and AnnexinV + / 7AAD + late apoptotic/necrotic cells in PBS, Steen, and HSA 7% samples versus untreated controls ( Figure S3) . Nonetheless, H 2 O 2 and 8-iso-PGF2a release in HUVECs supernatants after CS/NR were significantly lower in Steen solution compared to both PBS and 7% HSA (Figure 6A and B) , evidencing the antioxidant properties of Steen solution on endothelial cells. Recovery in Steen solution was also associated with significantly reduced expression of IL-1a, IL-6, and IL-8 genes versus PBS and 7% HSA ( Figure 3) ; other cytokines (IL-4, IL-10, IL-17, and tumor necrosis factor a) were not detectable in these conditions (data not shown).
Finally, we assessed which NOX isoforms were involved, and quantified 8-iso-PGF2a and H 2 O 2 release in HUVECs supernatants after recovery in PBS supplemented with specific NOX-isoforms inhibitors. Basal expression levels of NOX isoforms in HUVECs are shown in Figure S2C . NOX1, 2, and 4 seemed to be co-responsible for the observed effects, particularly concerning 8-iso-PGF2a levels ( Figure 6A and B) . Moreover, a reduced NOX2 activation in HUVECs was specifically detected after Steen recovery ( Figure 6C ).
Discussion
After the first EVLP application reported by Steen and colleagues, many preclinical and clinical studies have explored the efficacy of Steen solution for the outcome of lung reconditioning (2), but the cellular mechanisms involved have not been elucidated yet. In particular, it is unclear whether Steen solution is able to directly preserve lung tissue viability and repair capacity by exerting pleiotropic functions.
Here we show for the first time the antioxidant and biological effects of the Steen solution in an in vitro CS/NR model (closely mimicking EVLP-associated thermal injury) on a relevant population of epithelial/progenitor cells (10, 11) , and on endothelial cells, which are cell types that significantly contribute to lung tissue homeostasis and repair (7, 8) , and that are severely damaged during PGD (12) .
PS-forming cells contain 45% of Oct4+ cells (a wellrecognized stemness marker), and approximately 9% of cells with clonogenic ability, which is a fundamental feature of stem cells (11) . The majority of cells inside PSs are aquaporin-5, cytokeratin-5, and pro-surfactant-C positive (11), consistently with alveolar/basal epithelial phenotypes, overall resembling the lung's high plasticity. Moreover, we extended our observations to vascular cells by using HUVECs, a widely recognized in vitro model of normal, mature, and proliferative endothelial cells. HUVECs have been successfully employed to investigate the role of endothelium in different physiopathological responses, including LTx (18) . Therefore, HUVECs represent a reproducible and consistent model to study hypothermic preservation or pulmonary reconditioning storage solutions (18, 19) . Representative time-course of luminescence-based enzymatic assay for NOX activity; reaction product specificity was confirmed by signal decay after superoxide dismutase (SOD) addition to protein lysates. Measurement of 8-iso-PGF2a (C) and H 2 O 2 (D) concentrations in PSs culture supernatants after recovery in PBS supplemented with different specific NOX isoforms inhibitors, compared to control cell cultures. (E) Representative Western blot (WB) for NOX isoforms expression showing comparable protein levels in all conditions. (F) Measurement of soluble NOX2 peptide (sNOX2-dp) levels, as a marker of NOX2 activation, in PSs culture supernatants compared to cell cultures after recovery in PBS. (G) Average normalized densitometric analysis of P-p47 after recovery in 10% Steen solution, compared to PBS; control cell cultures are shown as references. (H) Representative WB for phosphorylated p47 (P-p47) after recovery in 10% Steen or PBS, supplemented or not with NOX2 inhibitor. A.U., arbitrary units; CS, cold starvation; CTR, control cells without stress; FC versus CTR, fold change versus control; n.s., not significant; phosphate-buffered saline; RLU, Relative Luminescence Units; SOD, superoxide dismutase. *p < 0.05. **p < 0.01. ***p < 0.001.
The present CS/NR approach allowed the evaluation of specific biological responses to perfusion solution in parenchymal cells, potentially contributing also to injury resolution and repair through dedifferentiation of epithelial cells and/or LPCs (7, 20) , independently of mechanical/ ventilatory stress.
Our study demonstrated that Steen solution exerts prosurvival effects on human primary lung spheroids of epithelial cells subjected to an in vitro model of CS/NR. These effects are associated with significant posttranscriptional reduction of NOX2 activity and ROS production. Importantly, NOX2 inhibition partially recapitulated the beneficial effects observed for Steen solution, suggesting that its pro-survival effects are partially but significantly mediated by NOX2 inhibition. Previous studies have demonstrated that NOX2 is activated after stress and significantly contributes to IRI (21) . We extended this evidence by demonstrating that NOX2 inhibition reduces lung epithelial cell death after CS/NR. Interestingly, these pro-survival effects were not evident in HUVECs, suggesting a stronger tolerance to oxidative stress, and highlighting a different biological behavior of the endothelium versus parenchymal/epithelial elements. This is further supported by the different modulation observed in inflammatory cytokines expression.
Although hypothermia followed by warm hypoxia reconditioning can severely affect in vitro endothelial cell viability and morphology (22) , our results suggest that the Steen solution fosters endothelial protection. Nonetheless, other biological variables responsible for endothelial integrity may be involved, independently of ROS production, likely including electrolytes (23, 24) .
Notably, NOX2 inhibition was also involved in reducing ROS production by HUVECs, albeit in a balanced way with other NOX isoforms, as expected based on endothelial physiological expression of the NADPH-system enzymes (25, 26) . This result strengthens our previous observation that the Steen solution mainly impacts the endothelium by interfering with the NADPH system.
The mechanisms whereby Steen solution reduces NOX2 activity in multiple cell types (immune, epithelial, progenitor, and endothelial), though, remain unclear. NOX2 is mainly posttranslationally regulated. Its activation occurs when p47phox is phosphorylated by protein kinase C (PKC), translocates to cellular membranes, and binds to NOX2/p22phox heterodimer, promoting activation. Consistently, we found that Steen solution does not significantly affect NOX2 protein abundance, whereas it reduces p47phox phosphorylation, indicating that it might reduce NOX2 activity by interfering with PKC signaling in response to CS/NR.
Interestingly, our results support that the detrimental effect of NOX activation in epithelial cells during CS/NR is due to NOX2. In fact, NOX1/NOX4 inhibitor did not exert beneficial effects, whereas NOX5 inhibitor was detrimental. NOX5 inhibition has been shown indeed to be pro-apoptotic in cancer cells (27) . Nonetheless, the protective mechanisms of NOX5 in nontransformed cells during CS/NR need further clarification. Conversely, all NOX isoforms tested were co-responsible for the oxidant mechanisms triggered by CS/NR in HUVECs.
Although the observed antioxidant effects of Steen solution in PSs and HUVECs are at least partly mediated by its nonspecific scavenging properties, they can be efficiently simulated by a specific NOX2 inhibitor, particularly in PSs. In fact, we also evaluated NOX2 isoform activity, one of the main ROS producers, which is activated during the CS/NR protocol (28), but recovery in Steen solution could significantly reduce NOX2 activation in both PSs and HUVECs. Thus, we envision an intracellular protective pathway for multiple lung cell types, particularly for epithelial cells and LPCs, whereby recovery in Steen solution specifically decreases NOX2 activation.
ROS act at physiological levels as intracellular messengers in multiple cell types, but are unstable molecules that can mediate IRI harmful effects (29) . Among them, H 2 O 2 is one of the most abundant and stable molecules in vivo for reliable quantification. H 2 O 2 stimulates 8-epi-PGF2a production, which represents the noncyclooxygenase-mediated metabolism of arachidonic acid, and reflects the levels of lipid peroxidation (16) . Our results consistently showed that ROS levels were significantly increased after CS/NR, and reduced by Steen solution in all cell types, indicating its protective effects during EVLP also by reducing IRI. (sNOX2-dp) levels in HUVEC culture supernatants after cold starvation and normothermic recovery. CTR, control cells without stress; HSA, human serum albumin; HUVEC, human umbilical vein endothelial cells; NOX, NADPH-oxidase; PBS, phosphate-buffered saline; ROS, reactive oxygen species. ***p < 0.001.
Decreasing detrimental ROS production during IRI has been previously proposed as a strategy for improving LTx; our recent contribution (6) and the present study further support this approach, evidencing for the first time the antioxidant properties of Steen solution on parenchymal cells through the downregulation of NOX activity, in particular of NOX2 isoform.
As mentioned above, LPCs contribute to lung homeostasis and repair in response to stress or injury (7, 8) . Intriguingly, our results suggest that Steen solution may maintain the integrity of donor lungs in EVLP also by preserving, at least in part, a regenerative cellular pool actively involved in injury resolution through resident LPCs and epithelial cells, which can behave like lung stem cells themselves (7, 8, 20, 30) .
The main limitations of the present study are the lack of controlled ventilation in the CS/NR protocol, albeit consistent with previous works by other authors (15) , and the cell type-restricted in vitro approach without a tissue-like organization, which needs to be further validated in vivo.
However, the present results add novel insights on the cellular mechanisms possibly activated in marginal lungs reconditioning during EVLP, which may be further improved through selective therapeutic strategies, such as targeting NOX2 activation. With further developments in its clinical application, EVLP could have an increasing significant impact on the severe shortage of donor lungs that strongly limits the survival of patients on LTx waiting lists.
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